Uncategorized

Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual Inflammasome Inhibitor K8

by Business Wire • 2024/01/18 • 0 Comments

NEWTON, Mass.--(BUSINESS WIRE)-- #NRTIs--Inflammasome Therapeutics announces first patient dosed in Phase 1 DME study of novel dual inflammasome inhibitor K8 to treat inflammation causing DME

← Chemify Partners with Prepaire Labs to Apply Ground-breaking Chemistry AI-Robotics to Radically Accelerate the Discovery of Non-Addictive Opioids

National Stem Cell Foundation Travels with Axiom Space Mission to Continue Innovative Neurodegeneration Research on the International Space Station →

Post navigation